These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 20685748

  • 1. Cardiovascular events in patients with COPD: TORCH study results.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J, TORCH Investigators.
    Thorax; 2010 Aug; 65(8):719-25. PubMed ID: 20685748
    [Abstract] [Full Text] [Related]

  • 2. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 3. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug 22; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 4. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM.
    Am J Respir Crit Care Med; 2008 Aug 15; 178(4):332-8. PubMed ID: 18511702
    [Abstract] [Full Text] [Related]

  • 5. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 15; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 6. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
    Thorax; 2005 Jun 15; 60(6):480-7. PubMed ID: 15923248
    [Abstract] [Full Text] [Related]

  • 7. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, Prillaman B, Shah T.
    Ann Allergy Asthma Immunol; 1999 Mar 15; 82(3):257-65. PubMed ID: 10094216
    [Abstract] [Full Text] [Related]

  • 8. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul 15; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

  • 9. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug 15; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

  • 10. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD.
    Dransfield MT, Cockcroft JR, Townsend RR, Coxson HO, Sharma SS, Rubin DB, Emmett AH, Cicale MJ, Crater GD, Martinez FJ.
    Respir Med; 2011 Sep 15; 105(9):1322-30. PubMed ID: 21696934
    [Abstract] [Full Text] [Related]

  • 11. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
    Clin Ther; 2007 Jul 15; 29(7):1390-402. PubMed ID: 17825690
    [Abstract] [Full Text] [Related]

  • 12. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP.
    Am J Med; 2006 Oct 15; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
    Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J.
    Respir Res; 2009 Jun 30; 10(1):59. PubMed ID: 19566934
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T.
    Am J Respir Crit Care Med; 2002 Oct 15; 166(8):1084-91. PubMed ID: 12379552
    [Abstract] [Full Text] [Related]

  • 15. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, VanderMeer A, Dorinsky P.
    Ann Allergy Asthma Immunol; 2004 Oct 15; 93(4):351-9. PubMed ID: 15521371
    [Abstract] [Full Text] [Related]

  • 16. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.
    Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P.
    Ann Allergy Asthma Immunol; 2005 Jul 15; 95(1):66-71. PubMed ID: 16095144
    [Abstract] [Full Text] [Related]

  • 17. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
    Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J.
    Eur Respir J; 2009 Sep 15; 34(3):641-7. PubMed ID: 19443528
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y.
    Am J Manag Care; 2009 Apr 15; 15(4):226-32. PubMed ID: 19355795
    [Abstract] [Full Text] [Related]

  • 19. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, TRial of Inhaled STeroids ANd long-acting beta2 agonists study group.
    Lancet; 2003 Feb 08; 361(9356):449-56. PubMed ID: 12583942
    [Abstract] [Full Text] [Related]

  • 20. Safety of salmeterol in the maintenance treatment of asthma.
    Nathan RA, Seltzer JM, Kemp JP, Chervinsky P, Alexander WJ, Liddle R, Mills R.
    Ann Allergy Asthma Immunol; 1995 Sep 08; 75(3):243-8. PubMed ID: 7552926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.